Viread, Genvoya(tenofovir)
Atripla, Biktarvy, Cimduo, Complera, Delstrigo, Descovy, Genvoya, Odefsey, Stribild, Symfi, Symtuza, Truvada, Vemlidy, Viread (tenofovir) is a small molecule pharmaceutical. Tenofovir was first approved as Viread on 2001-10-26. It is used to treat acquired immunodeficiency syndrome, chronic hepatitis b, hepatitis b, and HIV infections in the USA. It has been approved in Europe to treat hepatitis b and HIV infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
---|---|
infections | D007239 |
digestive system diseases | D004066 |
urogenital diseases | D000091642 |
immune system diseases | D007154 |
signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Viread (generic drugs available since 2015-03-18)
CombinationsAtripla, Cimduo, Complera, Delstrigo, Stribild, Symfi, Symfi lo, Truvada (generic drugs available since 2015-03-18, discontinued: Temixys)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cobicistat
+
Elvitegravir
+
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
STRIBILD | Gilead Sciences | N-203100 RX | 2012-08-27 | 1 products, RLD, RS |
Doravirine
+
Lamivudine
+
Tenofovir disoproxil fumarate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DELSTRIGO | Merck Sharp & Dohme | N-210807 RX | 2018-08-30 | 1 products, RLD, RS |
Efavirenz
+
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ATRIPLA | Gilead Sciences | N-021937 RX | 2006-07-12 | 1 products, RLD, RS |
Efavirenz
+
Lamivudine
+
Tenofovir disoproxil fumarate
Emtricitabine
+
Rilpivirine hydrochloride
+
Tenofovir disoproxil fumarate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
COMPLERA | Gilead Sciences | N-202123 RX | 2011-08-10 | 1 products, RLD, RS |
Emtricitabine
+
Tenofovir disoproxil fumarate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TRUVADA | Gilead Sciences | N-021752 RX | 2004-08-02 | 4 products, RLD, RS |
Lamivudine
+
Tenofovir disoproxil fumarate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
CIMDUO | Mylan | N-022141 RX | 2018-02-28 | 1 products, RLD, RS |
Show 2 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
atripla | New Drug Application | 2021-12-14 |
biktarvy | New Drug Application | 2022-11-30 |
cimduo | New Drug Application | 2021-02-15 |
complera access | Export only | 2021-03-29 |
delstrigo | New Drug Application | 2022-01-27 |
descovy | New Drug Application | 2022-01-13 |
emtricitabine and tenofovir disoproxil fumarate | ANDA | 2023-06-15 |
genvoya | New Drug Application | 2022-01-13 |
odefsey | New Drug Application | 2021-09-17 |
stribild | New Drug Application | 2021-09-16 |
Show 6 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
chronic hepatitis b | EFO_0004239 | D019694 | B18.1 |
hepatitis b | — | D006509 | — |
hiv infections | EFO_0000764 | D015658 | B20 |
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
DORAVIRINE / LAMIVUDINE / TENOFOVIR DISOPROXIL FUMARATE, DELSTRIGO, MSD MERCK CO | |||
2025-01-27 | NPP | ||
2023-08-30 | NCE |
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Doravirine / Lamivudine / Tenofovir Disoproxil Fumarate, Delstrigo, Msd Merck Co | |||
10603282 | 2036-11-29 | DP | |
10842751 | 2036-11-29 | DP | |
8486975 | 2031-10-07 | DS, DP | U-2395, U-2629, U-3307 |
Emtricitabine / Rilpivirine Hydrochloride / Tenofovir Disoproxil Fumarate, Complera, Gilead Sciences Inc | |||
10857102 | 2033-01-14 | DP | |
8841310 | 2025-12-09 | DP | U-257 |
7125879 | 2025-04-21 | DS, DP | U-257 |
8080551 | 2023-04-11 | DS, DP | |
Cobicistat / Elvitegravir / Emtricitabine / Tenofovir Disoproxil Fumarate, Stribild, Gilead Sciences Inc | |||
10039718 | 2032-10-06 | DP | |
8633219 | 2030-04-30 | DP | U-257 |
8148374 | 2029-09-03 | DS, DP | U-1279 |
9891239 | 2029-09-03 | DP | U-257 |
7635704 | 2026-10-26 | DS, DP | U-257 |
8981103 | 2026-10-26 | DS, DP | |
7176220 | 2026-08-27 | DS, DP | U-257 |
8592397 | 2024-01-13 | DP | U-248, U-257, U-541, U-750, U-1170 |
8716264 | 2024-01-13 | DP | U-257 |
9457036 | 2024-01-13 | DP | U-257 |
9744181 | 2024-01-13 | DP | U-257 |
Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate, Atripla, Gilead Sciences | |||
8598185 | 2029-04-28 | DP | |
9018192 | 2026-06-13 | U-750, U-1170 | |
9545414 | 2026-06-13 | DP | U-750, U-1170 |
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors
— J05AF07: Tenofovir disoproxil
— J05AF13: Tenofovir alafenamide
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR03: Tenofovir disoproxil and emtricitabine
— J05AR06: Emtricitabine, tenofovir disoproxil and efavirenz
— J05AR08: Emtricitabine, tenofovir disoproxil and rilpivirine
— J05AR09: Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
— J05AR11: Lamivudine, tenofovir disoproxil and efavirenz
— J05AR12: Lamivudine and tenofovir disoproxil
— J05AR17: Emtricitabine and tenofovir alafenamide
— J05AR18: Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
— J05AR19: Emtricitabine, tenofovir alafenamide and rilpivirine
— J05AR20: Emtricitabine, tenofovir alafenamide and bictegravir
— J05AR22: Emtricitabine, tenofovir alafenamide, darunavir and cobicistat
— J05AR24: Lamivudine, tenofovir disoproxil and doravirine
— J05AR27: Lamivudine, tenofovir disoproxil and dolutegravir
HCPCS
No data
Clinical
Clinical Trials
776 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 31 | 72 | 80 | 88 | 50 | 308 |
Chronic hepatitis b | D019694 | EFO_0004197 | B18.1 | 13 | 25 | 17 | 39 | 28 | 118 |
Hiv | D006678 | O98.7 | 18 | 11 | 16 | 52 | 22 | 117 | |
Hepatitis b | D006509 | 6 | 15 | 8 | 16 | 13 | 56 | ||
Healthy volunteers/patients | — | 23 | — | — | 7 | 2 | 32 | ||
Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 2 | 2 | 6 | 2 | 2 | 14 |
Infections | D007239 | EFO_0000544 | — | 3 | 6 | 3 | — | 12 | |
Medication adherence | D055118 | EFO_0006344 | 3 | 1 | 2 | 3 | 1 | 10 | |
Hiv-1 | D015497 | — | 2 | 3 | 4 | — | 9 | ||
Pregnancy | D011247 | EFO_0002950 | Z33.1 | 1 | 3 | 2 | 2 | — | 8 |
Show 42 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Covid-19 | D000086382 | U07.1 | — | 3 | 5 | — | 1 | 6 | |
Sars-cov-2 | D000086402 | — | 1 | 2 | — | — | 2 | ||
Chronic hepatitis d | D019701 | — | 1 | 1 | — | — | 2 | ||
Lymphoma | D008223 | C85.9 | 1 | 1 | 1 | — | — | 2 | |
Treatment adherence and compliance | D000074822 | — | — | 2 | — | — | 2 | ||
Breast feeding | D001942 | — | — | 1 | — | — | 1 | ||
Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | — | 1 | — | — | 1 |
B-cell lymphoma | D016393 | — | — | 1 | — | — | 1 | ||
Disease progression | D018450 | — | — | 1 | — | — | 1 | ||
Hiv seronegativity | D018023 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis d | D003699 | EFO_0007304 | — | 4 | — | — | — | 4 | |
Biliary liver cirrhosis | D008105 | K74.3 | — | 1 | — | — | 1 | 2 | |
Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | — | 1 | — | — | 1 | 2 |
Lipodystrophy | D008060 | E88.1 | — | 2 | — | — | — | 2 | |
Parasitemia | D018512 | 1 | 1 | — | — | — | 1 | ||
Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 1 | — | — | — | 1 |
Progressive multifocal leukoencephalopathy | D007968 | EFO_0007455 | A81.2 | — | 1 | — | — | — | 1 |
Amphetamine-related disorders | D019969 | EFO_0004701 | F15 | — | 1 | — | — | — | 1 |
B-cell chronic lymphocytic leukemia | D015451 | C91.1 | — | 1 | — | — | — | 1 | |
Large b-cell lymphoma diffuse | D016403 | C83.3 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug interactions | D004347 | 1 | — | — | — | 1 | 2 | ||
Contraception | D003267 | 1 | — | — | — | 1 | 2 | ||
Gender dysphoria | D000068116 | F64 | 1 | — | — | — | — | 1 | |
Transgenes | D019076 | 1 | — | — | — | — | 1 | ||
Insulin resistance | D007333 | EFO_0002614 | 1 | — | — | — | — | 1 | |
Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pregnancy rate | D018873 | — | — | — | — | 2 | 2 | ||
Risk reduction behavior | D040242 | — | — | — | — | 2 | 2 | ||
Sustained virologic response | D000072230 | — | — | — | — | 1 | 1 | ||
Job syndrome | D007589 | EFO_0003775 | D82.4 | — | — | — | — | 1 | 1 |
Inflammation | D007249 | — | — | — | — | 1 | 1 | ||
Infertility | D007246 | EFO_0000545 | — | — | — | — | 1 | 1 | |
Liver failure | D017093 | HP_0001399 | K72.9 | — | — | — | — | 1 | 1 |
Virus diseases | D014777 | B34 | — | — | — | — | 1 | 1 | |
Proteinuria | D011507 | HP_0000093 | R80 | — | — | — | — | 1 | 1 |
Hyperglycemia | D006943 | HP_0003074 | R73.9 | — | — | — | — | 1 | 1 |
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | TENOFOVIR |
INN | tenofovir |
Description | Tenofovir (anhydrous) is a member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection. It has a role as a HIV-1 reverse transcriptase inhibitor, an antiviral drug and a drug metabolite. It is a member of phosphonic acids and a nucleoside analogue. It is a conjugate acid of a tenofovir(1-). |
Classification | Small molecule |
Drug class | antivirals |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O |
Identifiers
PDB | — |
CAS-ID | 147127-20-6 |
RxCUI | 117466 |
ChEMBL ID | CHEMBL483 |
ChEBI ID | 63625 |
PubChem CID | 464205 |
DrugBank | DB00300 |
UNII ID | W4HFE001U5 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Stribild - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Truvada - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Atripla - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Viread - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Odefsey - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Vemlidy - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Genvoya - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Complera - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Descovy - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Biktarvy - Gilead Sciences
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 27,210 documents
View more details
Safety
Black-box Warning
Black-box warning for: Atripla, Biktarvy, Cimduo, Complera access, Delstrigo, Descovy, Emtricitabine and tenofovir disoproxil fumarate, Genvoya, Odefsey, Stribild, Symfi, Symtuza, Temixys, Truvada, Vemlidy, Viread
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
80,970 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more